The modern pharmaceutical economic system occupies a highly complex regulatory landscape where public healthcare demands, corporate intellectual property rights, and intense multi-tier commercial distribution channels intersect across global markets. Within this matrix, the underlying cost-accounting mechanisms of prescription legend drugs have historically operated behind a thick perimeter of trade-secret claims, confidential rebating compacts, and opaque […]